SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors react to a significant debt reduction move involving bond-for-equity exchanges alongside an extension for its 10-K filing. The community remains hyper-focused on the company's turnaround narrative and its substantial stake in Babcock & Wilcox, with many traders actively discussing the potential for a short squeeze as the market digests the balance sheet restructuring.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is surging following a strong quarterly earnings report that featured a revenue beat and upward-revised multi-year guidance driven by insatiable AI infrastructure demand. The stock is seeing heavy institutional interest as community sentiment aligns around the company's critical role in the data center buildout, with traders actively debating its path toward triple-digit price levels.

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals is surging following its acquisition by Biogen for approximately $5.6 billion, a deal that highlights strong sector interest in commercial-stage biotech assets. The community is actively discussing the successful exit for long-term shareholders who weathered volatility, while investors are now pivoting to identify other potential M&A candidates within the broader biotechnology landscape.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following the announcement of $100 million in new financing, including a $75 million non-dilutive royalty agreement with Oberland Capital, which investors view as a key move to scale global operations and strengthen the company's balance sheet without significant dilution. While the stock continues to face intense pressure from short sellers and speculative volatility, the community is actively debating the impact of this capital injection on future growth, profitability timelines, and the potential for a short squeeze as the company expands its immunotherapy reach into new markets.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is facing significant volatility as investors weigh the company's aggressive $8.5 billion infrastructure financing deal against broader market headwinds and persistent insider selling. While some traders view the recent dip as a tactical entry point bolstered by optimistic analyst price targets and institutional backing, others are concerned about debt leverage and the potential for a cooling AI sector.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

SPY is trending as market participants digest conflicting reports regarding the potential de-escalation of military hostilities in the Middle East, with traders debating whether recent headlines signal a genuine shift in policy or another tactical maneuver. The community remains heavily divided, with intense discussions focused on the economic implications of persistent energy volatility and the credibility of administration communications amid broader market instability.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is currently seeing heavy community interest driven by anticipation of major contract wins and follow-on orders for its ultra-high-power wafer-level test and burn-in systems, particularly from key hyperscale data center and AI processor customers. Investors are closely tracking timelines for evaluation milestones and follow-on purchase orders, viewing the stock as a critical, undervalued play on the infrastructure expansion required for next-generation AI and silicon photonics hardware.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is capturing significant investor attention as stakeholders connect the company's photonics platform to major AI infrastructure developments involving industry giants like NVIDIA and Marvell. While some in the community remain skeptical due to past production delays and the lack of immediate revenue, many are aggressively accumulating shares, betting that POET's co-development agreements will soon convert into high-volume commercial orders.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is under intense market scrutiny following a strategic $2 billion investment in Marvell Technology, a move aimed at fortifying AI infrastructure through specialized networking and high-performance computing. While the deal is being hailed by some as a vital signal of long-term AI scaling, the community remains deeply polarized, with many investors highlighting the stock's recent volatility, broader geopolitical instability, and concerns over unsustainable valuation multiples amidst a challenging macro environment.

Maase, Inc. engages in the provision of intelligent technology-driven family and enterprise services. It operates through the following business segments: Insurance Agency and Wealth Management. The Insurance Agency segment involves in providing agency services for distributing life and non-life insurance products on behalf of insurance companies. The Wealth Management segment offers financial advisory, investment planning, and asset management services for individuals, families, and corporate clients, utilizing data-driven insights and digital platforms to optimize financial outcomes. The company was founded by Hai Feng Yu on August 6, 2018, and is headquartered in Guangzhou, China.

Maase Inc. - Ordinary Shares - Class A

Highest Performances Holdings Inc. - ADR

MAAS is trending as investors react to its recent acquisition of Huazhi, a strategic pivot into proprietary AI compute and integrated algorithms that shifts the company's narrative from a traditional service operator to a technology-integrated AI platform. Community discussion is heavily split between retail traders analyzing the potential for a low-float momentum squeeze and skeptics raising red flags regarding past dilution and the influx of automated promotional activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SLS =/+/- 60 Events just from the Control Arm WHILE we Await 80.  
   
Shorts Selling the Price down on a Short Con - offering the investment Opportunity of a Lifetime.  
MARK THIS POST. 
 
BAT / aka Aza+VEN - recently FAILED 3 Large and Expensive Phase 3 Trials conducted by $ABBV - including FAILING 2 For AML REMISSION MAINTENANCE. 
 
Aza+VEN Also FAILED the REGAL Phase 3 Control Arm Patients -- now you know. 
 
Just Realize, Gps IS absolutely Golden, Getting FDA Approval and worth $40B to Big Pharma, and act accordingly.

Kris Kotsay

CMSP

$SLS Enrollment completed 24 months ago 
127/128 patients  
as of NOV 2023, 105 Patients Were Enrolled - 28 months ago 
Dr. Jamy was asked, how long patients on BAT survive: 
- he answers by saying, median OS for patients on BAT is Just 6-8 months even with the latest treatments Aza+VEN, &quot;You Will Not See Survival Past 12 months&quot;. 
- There are No Published Trials with AML Cr2 Patients Not Getting Transplant, with any Survival at 2 years ... ZERO. 
- there are NIL Control Patients Remaining ALIVE, just the rarest of Rare Outliers. 
=/+/- 60 Events just from the Control Arm WHILE we Await 80. 
  
Shorts Selling the Price down on a Short Con - offering the investment Opportunity of a Lifetime. 
MARK THIS POST.

StockTwits Web

SELLAS Life Sciences Group Inc

5,500% ROI this quarter

Abbvie Inc

 =/+/- 60 Events just from the Control Arm WHILE we Await 80.  
   
Shorts Selling the Price down on a Short Con - offering the investment Opportunity of a Lifetime.  
MARK THIS POST. 
 
BAT / aka Aza+VEN - recently FAILED 3 Large and Expensive Phase 3 Trials conducted by 

 - including FAILING 2 For AML REMISSION MAINTENANCE. 
 
Aza+VEN Also FAILED the REGAL Phase 3 Control Arm Patients -- now you know. 
 
Just Realize, Gps IS absolutely Golden, Getting FDA Approval and worth $40B to Big Pharma, and act accordingly.